Ardelyx Inc (ARDX)

$5.78 +0.12 (2.12%)
Market Cap 1.42B
Revenue (ttm) 407.32M
Net Income (ttm) -61.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.12%
Debt to Equity Ratio 1.21
Volume 2,775,100
Avg Vol 5,019,682
Day's Range N/A - N/A
Shares Out 245.25M
Stochastic %K 16%
Beta 0.61
Analysts Strong Sell
Price Target $16.10

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 745 1700
Address:
400 Fifth Avenue, Suite 210, Waltham, United States
Cjs2027
Cjs2027 Mar. 15 at 6:05 PM
$ARDX does anyone have a transcript of the oral arguments held in sep 2025? i only have the audio and been having a challenge generating the transcript itself. thanks!
1 · Reply
Cameohitch
Cameohitch Mar. 15 at 2:53 PM
$ARDX Would be quite the irony to get court case news on "National Phosphorus Awareness Day", right? "National Phosphorus Awareness Day is on 4.5 - Join us on April 5 (4.5) each year to learn about the impact of unmanaged phosphorus levels in individuals with advanced chronic kidney disease!" https://aakp.org/programs-and-events/national-phosphorus-awareness-day/
1 · Reply
Cameohitch
Cameohitch Mar. 15 at 2:53 PM
$ARDX Would be quite the irony to get court case news on "National Phosphorus Awareness Day", right? "National Phosphorus Awareness Day is on 4.5 - Join us on April 5 (4.5) each year to learn about the impact of unmanaged phosphorus levels in individuals with advanced chronic kidney disease!" https://aakp.org/programs-and-events/national-phosphorus-awareness-day/
2 · Reply
mrbigstakes
mrbigstakes Mar. 15 at 10:11 AM
$ARDX Great news!!
0 · Reply
Cameohitch
Cameohitch Mar. 15 at 9:34 AM
$ARDX New paper out "Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD Stages 3-5" "As a targeted therapy, Tenapanor offers a low drug load, which a key factor in medication compliance, especially in end-stage CKD where phosphate binders account for 50% of total pill burden.15,54 Drug load (dose × frequency) is largely dose-dependent when dosing frequency is fixed. Thus, agents with lower doses or higher phosphate-lowering efficiency (e.g., TE, PA21) may improve compliance. Observational and RCTs data suggest LC has suboptimal compliance, likely due to its metallic taste.55 Metal-based binders generally require additional patient education to address tolerability and administration challenges." https://www.sciencedirect.com/science/article/pii/S2590059526000920
1 · Reply
Cameohitch
Cameohitch Mar. 15 at 9:34 AM
$ARDX New paper out "Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD Stages 3-5" "As a targeted therapy, Tenapanor offers a low drug load, which a key factor in medication compliance, especially in end-stage CKD where phosphate binders account for 50% of total pill burden.15,54 Drug load (dose × frequency) is largely dose-dependent when dosing frequency is fixed. Thus, agents with lower doses or higher phosphate-lowering efficiency (e.g., TE, PA21) may improve compliance. Observational and RCTs data suggest LC has suboptimal compliance, likely due to its metallic taste.55 Metal-based binders generally require additional patient education to address tolerability and administration challenges." https://www.sciencedirect.com/science/article/pii/S2590059526000920
0 · Reply
opportoni
opportoni Mar. 15 at 9:10 AM
$ARDX I‘ll put this out very plain and simple: What we have here is a $5 billion enterprise valued at $1.4 billion.
1 · Reply
GladysFoster
GladysFoster Mar. 14 at 6:24 PM
$ARDX where is our positive appeal decision?
3 · Reply
donkeykongreturns
donkeykongreturns Mar. 14 at 2:16 AM
$ARDX A lot of pharma is shrinking right now while Ardx keeps growing.
0 · Reply
FerreroRocher
FerreroRocher Mar. 13 at 11:02 PM
$ARDX All 30 sales job positions.
3 · Reply
Latest News on ARDX
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Mar 12, 2026, 8:00 AM EDT - 3 days ago

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Mar 9, 2026, 4:05 PM EDT - 6 days ago

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Ardelyx to Participate in Upcoming Investor Conferences

Mar 4, 2026, 8:00 AM EST - 11 days ago

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Feb 24, 2026, 8:00 AM EST - 19 days ago

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Feb 21, 2026, 3:25 AM EST - 22 days ago

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Feb 20, 2026, 11:12 AM EST - 23 days ago

Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability

Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops

Feb 20, 2026, 6:50 AM EST - 23 days ago

Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops

Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript

Feb 20, 2026, 2:44 AM EST - 23 days ago

Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 19, 2026, 4:01 PM EST - 24 days ago

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Feb 5, 2026, 8:00 AM EST - 5 weeks ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Ardelyx Receives New Patent for Tenapanor

Feb 3, 2026, 8:29 AM EST - 5 weeks ago

Ardelyx Receives New Patent for Tenapanor

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

Jan 28, 2026, 8:29 AM EST - 6 weeks ago

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

Ardelyx: Assessment Of Acquisition Rumors

Jan 21, 2026, 1:04 PM EST - 7 weeks ago

Ardelyx: Assessment Of Acquisition Rumors

Ardelyx: IBSRELA Momentum Drives Opportunity

Jan 20, 2026, 6:14 AM EST - 7 weeks ago

Ardelyx: IBSRELA Momentum Drives Opportunity

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Jan 8, 2026, 8:30 AM EST - 2 months ago

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Nov 7, 2025, 4:05 PM EST - 4 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Nov 5, 2025, 8:00 AM EST - 4 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Ardelyx: Impressive Q3 Record Growth - Why I Buy

Nov 5, 2025, 4:24 AM EST - 4 months ago

Ardelyx: Impressive Q3 Record Growth - Why I Buy

Ardelyx: A Long Overdue Rally

Nov 4, 2025, 3:32 PM EST - 4 months ago

Ardelyx: A Long Overdue Rally

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Nov 4, 2025, 8:00 AM EST - 4 months ago

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 11:06 PM EDT - 4 months ago

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 30, 2025, 4:01 PM EDT - 4 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Oct 28, 2025, 8:01 AM EDT - 4 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Oct 21, 2025, 8:00 AM EDT - 5 months ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Oct 13, 2025, 8:35 AM EDT - 5 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Oct 13, 2025, 8:30 AM EDT - 5 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:11 AM EDT - 6 months ago

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 4:42 PM EDT - 6 months ago

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Aug 15, 2025, 6:17 AM EDT - 7 months ago

Ardelyx: Improved Outlook For Ibsrela And Xphozah

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:11 PM EDT - 7 months ago

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:08 PM EDT - 7 months ago

Ardelyx Announces Changes to the Executive Leadership Team

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:01 PM EDT - 7 months ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jul 21, 2025, 8:00 AM EDT - 8 months ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Jun 2, 2025, 4:05 PM EDT - 10 months ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 21, 2025, 8:00 AM EDT - 10 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 6, 2025, 8:01 AM EDT - 11 months ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

May 2, 2025, 10:07 AM EDT - 11 months ago

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

May 1, 2025, 10:06 PM EDT - 11 months ago

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:01 PM EDT - 11 months ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 29, 2025, 8:00 AM EDT - 11 months ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Cjs2027
Cjs2027 Mar. 15 at 6:05 PM
$ARDX does anyone have a transcript of the oral arguments held in sep 2025? i only have the audio and been having a challenge generating the transcript itself. thanks!
1 · Reply
Cameohitch
Cameohitch Mar. 15 at 2:53 PM
$ARDX Would be quite the irony to get court case news on "National Phosphorus Awareness Day", right? "National Phosphorus Awareness Day is on 4.5 - Join us on April 5 (4.5) each year to learn about the impact of unmanaged phosphorus levels in individuals with advanced chronic kidney disease!" https://aakp.org/programs-and-events/national-phosphorus-awareness-day/
1 · Reply
Cameohitch
Cameohitch Mar. 15 at 2:53 PM
$ARDX Would be quite the irony to get court case news on "National Phosphorus Awareness Day", right? "National Phosphorus Awareness Day is on 4.5 - Join us on April 5 (4.5) each year to learn about the impact of unmanaged phosphorus levels in individuals with advanced chronic kidney disease!" https://aakp.org/programs-and-events/national-phosphorus-awareness-day/
2 · Reply
mrbigstakes
mrbigstakes Mar. 15 at 10:11 AM
$ARDX Great news!!
0 · Reply
Cameohitch
Cameohitch Mar. 15 at 9:34 AM
$ARDX New paper out "Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD Stages 3-5" "As a targeted therapy, Tenapanor offers a low drug load, which a key factor in medication compliance, especially in end-stage CKD where phosphate binders account for 50% of total pill burden.15,54 Drug load (dose × frequency) is largely dose-dependent when dosing frequency is fixed. Thus, agents with lower doses or higher phosphate-lowering efficiency (e.g., TE, PA21) may improve compliance. Observational and RCTs data suggest LC has suboptimal compliance, likely due to its metallic taste.55 Metal-based binders generally require additional patient education to address tolerability and administration challenges." https://www.sciencedirect.com/science/article/pii/S2590059526000920
1 · Reply
Cameohitch
Cameohitch Mar. 15 at 9:34 AM
$ARDX New paper out "Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD Stages 3-5" "As a targeted therapy, Tenapanor offers a low drug load, which a key factor in medication compliance, especially in end-stage CKD where phosphate binders account for 50% of total pill burden.15,54 Drug load (dose × frequency) is largely dose-dependent when dosing frequency is fixed. Thus, agents with lower doses or higher phosphate-lowering efficiency (e.g., TE, PA21) may improve compliance. Observational and RCTs data suggest LC has suboptimal compliance, likely due to its metallic taste.55 Metal-based binders generally require additional patient education to address tolerability and administration challenges." https://www.sciencedirect.com/science/article/pii/S2590059526000920
0 · Reply
opportoni
opportoni Mar. 15 at 9:10 AM
$ARDX I‘ll put this out very plain and simple: What we have here is a $5 billion enterprise valued at $1.4 billion.
1 · Reply
GladysFoster
GladysFoster Mar. 14 at 6:24 PM
$ARDX where is our positive appeal decision?
3 · Reply
donkeykongreturns
donkeykongreturns Mar. 14 at 2:16 AM
$ARDX A lot of pharma is shrinking right now while Ardx keeps growing.
0 · Reply
FerreroRocher
FerreroRocher Mar. 13 at 11:02 PM
$ARDX All 30 sales job positions.
3 · Reply
MedHS55
MedHS55 Mar. 13 at 8:27 PM
$ARDX Happy it ended green, but that being said, yesterday's move of down $.33 and today's increase of $.12 was done on almost the exact number of shares..but there's no manipulation...🤣
1 · Reply
FerreroRocher
FerreroRocher Mar. 13 at 8:00 PM
$ARDX Is it Monday yet?
0 · Reply
Sven1988
Sven1988 Mar. 13 at 7:57 PM
$ARDX comical
0 · Reply
Capitulation_0
Capitulation_0 Mar. 13 at 7:55 PM
$ARDX Just find this interesting...Not suggesting that ARDX will play out in similar fashion but really speaks to Rabbs ability... Rabb was appointed chair of $FOLD on 3/2024, stock was trading $11-$13. In Jan 2025, the stock was trading around $5 due to missing guidance and high expenses. After this, he prioritized the global launch and revenue growth of Galafold (for Fabry disease) and Pombiliti + Opfolda (for Pompe disease). These products achieved significant combined product revenues (approx. $599M in late 2025), making the company an attractive acquisition target. One of the fastest turnaround story that ended with a Buyout at $14.5 -- all cash.
0 · Reply
PompousPilot
PompousPilot Mar. 13 at 7:53 PM
$ARDX Should be down to zero by the end of the day per usual
0 · Reply
ToadTrader
ToadTrader Mar. 13 at 5:05 PM
$ARDX Likely, most have "blocked" your postings.... Me? I sarcastically, enjoy your Clown Show...
0 · Reply
Capitulation_0
Capitulation_0 Mar. 13 at 4:53 PM
$ARDX maybe you all knew.. I didn't 1. Chairman of the Board (The Acquisition Period) Raab was appointed Chairman of the Board in March 2024, succeeding founder John F. Crowley. In this capacity, he oversaw the strategic direction of the company during the negotiations and final agreement for BioMarin to acquire Amicus for approximately $4.8 billion ($14.50 per share in cash).
0 · Reply
ToadTrader
ToadTrader Mar. 13 at 4:42 PM
$ARDX There is no place like "home".... No place like.... Tested Lower.... Tested Higher.... Centered once again... While the "Toad Range Theory" (like a broken clock... right twice a day!) is effective in understanding where price will move, the duration of time and the magnitude of the move within each "LEG" or "REACH", is yet to be perfected as a prediction aid! All that I have come to accept, thus adapt to trading between the lines! So,,, Dance the Core Line ($5.81) once again.... wait for the tide to move in your choice of a trading direction, then "RIDE THE WAVE" CHEERS!
2 · Reply
opportoni
opportoni Mar. 13 at 4:02 PM
$ARDX What‘s this? XBI down and we hold our gains?
2 · Reply
Orion_Laverne
Orion_Laverne Mar. 13 at 3:39 PM
$ARDX
0 · Reply
opportoni
opportoni Mar. 13 at 2:26 PM
$ARDX No opinion for us today. The two cases that got one were argued on September 30 and November 21, respectively. It is only a matter of time to get this off the table one way or another.
5 · Reply
Capitulation_0
Capitulation_0 Mar. 13 at 2:07 PM
$ARDX right up against support... typical
0 · Reply